Resource Summary Report

Generated by NIF on Sep 18, 2026

NCI-H716

RRID:CVCL_1581
Type: Cell Line

Proper Citation

RRID:CVCL_1581

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1581

Proper Citation: RRID:CVCL_1581

Description: Cell line NCI-H716 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cecum adenocarcinoma

Defining Citation: PMID:1359704, PMID:3479249, PMID:8806089, PMID:8806092, PMID:8806095, PMID:16418264, PMID:18258742, PMID:19927377, PMID:20164919, PMID:20215515, PMID:20606684, PMID:22460905, PMID:23272949, PMID:24755471, PMID:25485619, PMID:25877200, PMID:25926053, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28854368, PMID:29101300, PMID:29444439, PMID:29787053, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Characteristics: Secretes high level of glucagon-like peptide 1 (GLP-1) (PubMed=29787053)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H716

Synonyms: NCI H716, H716, H-716, NCIH716

Cross References: BTO:BTO_0004747, CLO:CLO_0008108, EFO:EFO_0002301, CLDB:cl3658, AddexBio:C0009022/5006, ArrayExpress:E-MTAB-38, ArrayExpress:E-

MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-251, BCRC:60517, BioGRID_ORCS_Cell_line:520, BioSample:SAMN03473254, BioSample:SAMN10987641, cancercelllines:CVCL_1581, CCRID:1101HUM-PUMC000359, CCRID:3101HUMTCHu210, CCTCC:GDC0163, Cell_Model_Passport:SIDM00779, ChEMBL-Cells:CHEMBL3308297, ChEMBL-Targets:CHEMBL2366106, CLS:305079, ColonAtlas:NCIH716, Cosmic:687536, Cosmic:908458, Cosmic:1995589, Cosmic:2302001, Cosmic-CLP:908458, DepMap:ACH-000491, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908458, GEO:GSM513917, GEO:GSM514304, GEO:GSM887443, GEO:GSM888523, GEO:GSM1346850, GEO:GSM1374759, GEO:GSM1448144, GEO:GSM1670259, IARC_TP53:21579, IARC_TP53:21743, IGRhCellID:NCIH716, KCLB:10251, LiGeA:CCLE_373, LINCS_LDP:LCL-1339, PharmacoDB:NCIH716_1130_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1581, PubChem_Cell_line:CVCL_1581, SKY/M-FISH/CGH:5013, Ubigene:YC-C112, Wikidata:Q54908110

ID: CVCL_1581

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260913T004957+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H716.

No alerts have been found for NCI-H716.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 109 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Passeri D, et al. (2026) Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. ChemMedChem, 21(2), e202500960.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. eLife, 13.

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. Cell reports. Medicine, 6(7), 102213.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. Cell reports. Medicine, 5(5), 101523.

Hosseini A, et al. (2024) Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell reports, 43(2), 113684.

Lee SP, et al. (2023) Thymoquinone activates imidazoline receptor to enhance glucagon-like peptide-1 secretion in diabetic rats. Archives of medical science : AMS, 19(1), 209.

Shon WJ, et al. (2023) Gut taste receptor type 1 member 3 is an intrinsic regulator of Western diet-induced intestinal inflammation. BMC medicine, 21(1), 165.

Lee SH, et al. (2023) Isosinensetin Stimulates Glucagon-like Peptide-1 Secretion via Activation of hTAS2R50 and the G??-Mediated Signaling Pathway. International journal of molecular sciences, 24(4).

Chapelet G, et al. (2023) Tau expression and phosphorylation in enteroendocrine cells. Frontiers in neuroscience, 17, 1166848.

Larraufie P, et al. (2023) Regulation of enteroendocrine cell respiration by the microbial metabolite hydrogen sulfide. Frontiers in endocrinology, 14, 1123364.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer discovery, 13(9), 2012.

Zhong J, et al. (2022) Rational design of a sensitivity-enhanced tracer for discovering efficient APC-Asef inhibitors. Nature communications, 13(1), 4961.

Yan Y, et al. (2022) Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism. Nature communications, 13(1), 6408.

Guo Y, et al. (2022) Circ_RNF13 Regulates the Stemness and Chemosensitivity of Colorectal Cancer by Transcriptional Regulation of DDX27 Mediated by TRIM24 Stabilization. Cancers, 14(24).

Shigemori K, et al. (2022) Peripheral A? acts as a negative modulator of insulin secretion. Proceedings of the National Academy of Sciences of the United States of America, 119(12), e2117723119.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(23), 5190.

Sachdev P, et al. (2022) Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE). Cancers, 14(18).

Zingg D, et al. (2022) Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), 609.

Lenos KJ, et al. (2022) Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nature communications, 13(1), 4443.

Jiang Y, et al. (2022) 18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis. Theranostics, 12(14), 6395.